CHARLOTTE, NC -- (MARKET WIRE) -- March 05, 2007 -- BurnsAdler Pharmaceuticals, Inc. (“BurnsAdler”) announced today that it has entered into a long-term licensing and supply agreement with X-GEN Pharmaceuticals, Inc. (“X-GEN”) for the company’s Colistimethate for Injection USP product. BurnsAdler intends to market Colistimethate for Injection USP in Mexico, particularly to fulfill an unmet therapeutic need. Colistimethate for Injection USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, such as Escherichia Coli (E. Coli), Pseudomonas aeruginosa and Klebsiella Pnumoniae.
